Alaunos Therapeutics (TCRT) Return on Sales (2011 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Return on Sales came in at 243.97% in Q1 2026, down 23851.0% YoY from N/an in Q1 2025, and down 7969.57% on a QoQ basis from 3.02% in Q4 2025.
Alaunos Therapeutics (TCRT) Return on Sales (2011 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 14 years of Return on Sales data on file, last reported at 243.97% in Q1 2026.
- Quarterly Return on Sales fell 23851.0% year-over-year to 243.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 243.97% (down 23981.0% YoY) and the FY2025 annual result came in at 435.62%, down 43081.0% from the prior year.
- Return on Sales eased to 243.97% in Q1 2026, from 3.02% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 53.91% in Q3 2023 to a low of 243.97% in Q1 2026.
- A 5-year average of 34.29% and a median of 3.02% in 2025 frame the typical range for Return on Sales.
- Annual changes were most pronounced in 2024 — Return on Sales surged 7902 bps — and 2026, when it sank 23851 bps.
- Tracing TCRT's Return on Sales over 5 years: stood at 8.56% in 2022, then plunged by 1045 bps to 80.91% in 2023, then surged by 98 bps to 1.89% in 2024, then tumbled by 60 bps to 3.02% in 2025, then sank by 7970 bps to 243.97% in 2026.
- The last three Return on Sales figures came in at 243.97% (Q1 2026), 3.02% (Q4 2025), and 121.83% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -13.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -243.97% |
| Dec 31, 2025 | -3.02% |
| Sep 30, 2025 | -121.83% |
| Jun 30, 2025 | -121.75% |
| Mar 31, 2025 | -5.46% |
| Dec 31, 2024 | -1.89% |
| Sep 30, 2024 | -20.25% |
| Jun 30, 2024 | -2.92% |
| Mar 31, 2024 | -17.42% |
| Dec 31, 2023 | -80.91% |
| Sep 30, 2023 | 53.91% |
| Jun 30, 2023 | -22.71% |
| Mar 31, 2023 | -0.13% |
| Dec 31, 2022 | 8.56% |
| Sep 30, 2022 | -0.03% |
| Jun 30, 2022 | -1.36% |
| Mar 31, 2022 | -1.70% |
| Dec 31, 2021 | -59.04% |
| Sep 30, 2021 | -0.57% |
| Dec 31, 2018 | -3.83% |